TY  - JOUR
T1  - Latest Advances in Gene Therapy in Management of Cystic Fibrosis Lung Disease, Literature Review
A1  - Saad Saeed Alghamdi
A1  - Naif Mohammed Alhamyani
A1  - Hamzah Mohammed Alamri
A1  - Thamer Saad Alzahrani
A1  - Sultan Mousa Daghas
A1  - Rayan Hussain Bakri
A1  - Ahmad Foad Basehi
A1  - Abdullatif Sanad Almarashi
A1  - Abdulrahman Mohammed Alrajehi
A1  - Danah Zaki Al Ghanim
A1  - Abdulaziz Jarallah Alobaidi
A1  - Ibrahim Ali Mahmood Alsahabi
A1  - Mariam Mohammed AlRawi
JF  - Journal of Biochemical Technology
JO  - J Biochem Technol
SN  - 0974-2328
Y1  - 2021
VL  - 12
IS  - 1
DO  - 10.51847/Usni3JotHd
SP  - 67
EP  - 70
N2  - Cystic fibrosis is an autosomal recessive disease that affects ion channels on epithelial cells. This leads to thicker and dysfunctional secretions. This can be evident when looking at the major symptoms of CF patients, which include recurrent respiratory tract infections and pancreatic insufficiency. The current management options for CF are either to manage the symptoms or modulate the existing defective genes. Gene therapy aims to correct dysfunctional genes as a way to cure the disease. We aimed to review the literature looking into gene therapy for cystic fibrosis, along with the advancements and current limitations. PubMed database was used for articles selection, papers were obtained and reviewed. There are multiple options for gene therapy in cystic fibrosis. This includes either introducing wild, working genes to the epithelial cells of the respiratory tract, or editing the defective genes. Gene replacement therapy is limited due to the nature of airway administration and the harsh environment of the airway of CF patients. Gene-editing therapy, however, is still under heavy research as it may offer a potential cure for this disease. 
UR  - https://jbiochemtech.com/article/latest-advances-in-gene-therapy-in-management-of-cystic-fibrosis-lung-disease-literature-review-2hah7yk5jti1sre
ER  -